Leveraging Advanced Drug Delivery Systems to Improve Clinical Viability

Advanced therapeutics are expanding faster than the industry’s ability to deliver them reliably in vivo. While the biology of mRNA, siRNA, or proteins may be compelling, their ultimate clinical viability depends entirely on the delivery system.

In this exclusive interview, Jerry Williamson, Chief Executive Officer of Phosphorex, explores the evolving drug-delivery landscape and reveals why “imprudent acceleration” in early-phase development can lead to a false sense of progress.

Discover how to bridge the gap between a promising therapeutic concept and a scalable, reproducible drug product

Download Content

First Name *

Last Name *

Job Title *

Company *

Country *

Phone

Email *

The LNP Alliance is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below to say how you would like us to contact you:

I agree to receive other communications from The LNP Alliance.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

By clicking submit below, you consent to allow The LNP Alliance to store and process the personal information submitted above to provide you the content requested.